Novel β-mannanase/GLP-1 fusion peptide high effectively ameliorates obesity in a mouse model by modifying balance of gut microbiota

Author(s):  
Yan Wang ◽  
Nuraliya Ablimit ◽  
Yunpeng Zhang ◽  
Jifu Li ◽  
Xinrui Wang ◽  
...  
2021 ◽  
Author(s):  
Mei Ji ◽  
Cheng Fang ◽  
Wei Jia ◽  
Hai Du ◽  
Yan Xu

Ethanol (EtOH) is the main risk factor for alcoholic liver disease. However, fermented alcoholic beverages contain not only ethanol but also various volatile compounds. Currently, effects of volatile compounds in...


Life Sciences ◽  
2021 ◽  
pp. 119675
Author(s):  
Mariana Angoa-Pérez ◽  
Branislava Zagorac ◽  
Dina M. Francescutti ◽  
Kevin R. Theis ◽  
Donald M. Kuhn

Cells ◽  
2021 ◽  
Vol 10 (4) ◽  
pp. 779
Author(s):  
Pradeep K. Shukla ◽  
David F. Delotterie ◽  
Jianfeng Xiao ◽  
Joseph F. Pierre ◽  
RadhaKrishna Rao ◽  
...  

Alzheimer’s disease (AD), a progressive neurodegenerative disorder characterized by memory loss and cognitive decline, is a major cause of death and disability among the older population. Despite decades of scientific research, the underlying etiological triggers are unknown. Recent studies suggested that gut microbiota can influence AD progression; however, potential mechanisms linking the gut microbiota with AD pathogenesis remain obscure. In the present study, we provided a potential mechanistic link between dysbiotic gut microbiota and neuroinflammation associated with AD progression. Using a mouse model of AD, we discovered that unfavorable gut microbiota are correlated with abnormally elevated expression of gut NLRP3 and lead to peripheral inflammasome activation, which in turn exacerbates AD-associated neuroinflammation. To this end, we observe significantly altered gut microbiota compositions in young and old 5xFAD mice compared to age-matched non-transgenic mice. Moreover, 5xFAD mice demonstrated compromised gut barrier function as evident from the loss of tight junction and adherens junction proteins compared to non-transgenic mice. Concurrently, we observed increased expression of NLRP3 inflammasome and IL-1β production in the 5xFAD gut. Consistent with our hypothesis, increased gut–microbial–inflammasome activation is positively correlated with enhanced astrogliosis and microglial activation, along with higher expression of NLRP3 inflammasome and IL-1β production in the brains of 5xFAD mice. These data indicate that the elevated expression of gut–microbial–inflammasome components may be an important trigger for subsequent downstream activation of inflammatory and potentially cytotoxic mediators, and gastrointestinal NLRP3 may promote NLRP3 inflammasome-mediated neuroinflammation. Thus, modulation of the gut microbiota may be a potential strategy for the treatment of AD-related neurological disorders in genetically susceptible hosts.


2021 ◽  
Vol 40 (1) ◽  
pp. 181-189 ◽  
Author(s):  
Jonathan Breton ◽  
Pauline Tirelle ◽  
Soujoud Hasanat ◽  
Arthur Pernot ◽  
Clément L'Huillier ◽  
...  

2017 ◽  
Vol 19 (suppl_6) ◽  
pp. vi78-vi78 ◽  
Author(s):  
Braden McFarland ◽  
Kory Dees ◽  
Nathalia Melo ◽  
Samuel Fehling ◽  
Sara Gibson ◽  
...  

2019 ◽  
Author(s):  
Min Wang ◽  
William Kwame Amakye ◽  
Jianing Cao ◽  
Congcong Gong ◽  
Xiaoyu Sun ◽  
...  

Abstract Background: Dysbiosis of gut microbiota is associated with the progression of beta-amyloid (Aβ) pathology in Alzheimer’s disease (AD). We aimed to identify uniform Aβ-responsible gut microbiota status as possible guideline for gut microbiota manipulation and the prediction of outcomes of microbiota targeted treatments. Six months old APP/PS1 mice from the same genetic background, housing and feeding conditions were then daily gavage with Metformin, peptides WN5 or PW5 to manipulate the gut microbiota for 12 weeks. Aβ pathology and gut microbiota were then explored and compared. Results: Fecal microbiota transplantation (FMT) from a 16 month old APP/PS1 mouse reconstituted the gut microbiota towards the donor and increased Aβ pathology in APP/PS1 mouse model. Metformin, peptides WN5 and PW5 all attenuated Aβ-plaque formation in APP/PS1 mouse model but each was associated with distinct gut microbiota status. No uniform gut microbiota pattern associated with Aβ pathology was found among different gut microbiota-targeted treatments. Conclusion: We found no uniform gut microbiota status associated with Aβ pathology suggesting gut microbiota status is not a suitable biomarker for AD diagnosis and treatment predictions. Alteration of gut microbiota in itself may not be sufficiently directly related to functional outcomes and might only be a shadow of deeper molecular mechanisms not fully understood. The findings here strongly suggested that the significance of gut microbiota alteration in disease pathology and treatment may have so far been over claimed and that interpretation of gut microbiota data should be done with utmost caution.


2020 ◽  
Vol 40 ◽  
pp. 425
Author(s):  
J. Breton ◽  
P. Tirelle ◽  
S. Hasanat ◽  
A. Pernot ◽  
C. L'Huillier ◽  
...  

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Alice Chaplin ◽  
Huiyun Gao ◽  
Courteney Asase ◽  
Palanivel Rengasamy ◽  
Bongsoo Park ◽  
...  
Keyword(s):  

An amendment to this paper has been published and can be accessed via a link at the top of the paper.


Sign in / Sign up

Export Citation Format

Share Document